Joint safety and neurologic events with subcutaneous tanezumab or oral nonsteroidal anti-inflammatory drugs in subgroups of patients with osteoarthritis from an 80-week phase 3 study

Abstract

Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in clinical development for the treatment of moderate to severe chronic pain of osteoarthritis (OA). A randomized, double-blind, double-dummy, active-controlled phase 3 study investigated the long-term safety and efficacy of subcutaneous (SC) tanezumab versus oral nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with hip or knee OA (NCT02528188). Here we examine the incidence of long-term joint safety and neurologic events in select subgroups of patients treated in this phase 3 study.